|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Mezger, Kerstin; Ebert, Sabine; Muhle, Hannah Elisa; Stadt, Udo zur; Borkhardt, Arndt; Dilloo, Dagmar; Faber, Jörg; Feuchtinger, Tobias; Imschweiler, Thomas; Jorch, Norbert; Pekrun, Arnulf; Schmid, Irene; Schramm, Franziska; Zimmermann, Martin; Horstmann, Martin A. und Escherich, Gabriele
(2022):
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
In: Pediatric Blood & Cancer, Bd. 69, Nr. 12, e29997
Escherich, Gabriele; Zur Stadt, Udo; Borkhardt, Arndt; Dilloo, Dagmar; Faber, Joerg; Feuchtinger, Tobias; Imschweiler, Thomas; Jorch, Norbert; Pekrun, Arnulf; Schmid, Irene; Schramm, Franziska; Spohn, Michael; Zimmermann, Martin und Horstmann, Martin A.
(2022):
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
In: Haematologica, Bd. 107, Nr. 5: S. 1026-1033
Schramm, Franziska; zur Stadt, Udo; Zimmermann, Martin; Jorch, Norbert; Pekrun, Arnulf; Borkhardt, Arndt; Imschweiler, Thomas; Christiansen, Holger; Faber, Jörg; Schmid, Irene; Feuchtinger, Tobias; Beron, Gerhard; den Boer, Monique L.; Pieters, Rob; Horstmann, Martin A.; Janka-Schaub, Gritta E. und Escherich, Gabriele
(2019):
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
In: Blood Advances, Bd. 3, Nr. 22: S. 3688-3699
Schramm, Franziska; Zimmermann, Martin; Jorch, Norbert; Pekrun, Arnulf; Borkhardt, Arndt; Imschweiler, Thomas; Christiansen, Holger; Faber, Jörg; Feuchtinger, Tobias; Schmid, Irene; Beron, Gerhard; Horstmann, Martin A. und Escherich, Gabriele
(2019):
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
In: Leukemia & Lymphoma, Bd. 60, Nr. 1: S. 60-68